Pituitary Adenylate Cyclase-Activating Polypeptide Prevents Cisplatin-Induced Renal Failure

• Published in: Journal of molecular neuroscience Vol. 43; no. 1; pp. 58 - 66
• Main Authors: Li, Min, Balamuthusamy, Saravanan, Khan, Altaf M., Maderdrut, Jerome L., Simon, Eric E., Batuman, Vecihi
• Format: Journal Article
• Language: English
• Published: New York Humana Press Inc 01.01.2011; Springer Nature B.V
• Subjects: Animals; Apoptosis; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cells, Cultured; Chemotherapy; Cisplatin - toxicity; Creatinine; Cytokines; Drug dosages; Extracellular Matrix - chemistry; Humans; Ischemia; Kidney Tubules - cytology; Kidney Tubules - pathology; Kidneys; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple myeloma; Neurochemistry; Neurology; Neurosciences; Octamer Transcription Factor-3 - genetics; Octamer Transcription Factor-3 - metabolism; Pituitary Adenylate Cyclase-Activating Polypeptide - therapeutic use; Polypeptides; Proliferating Cell Nuclear Antigen - genetics; Proliferating Cell Nuclear Antigen - metabolism; Proteomics; Renal Insufficiency - chemically induced; Renal Insufficiency - prevention & control; Tumor Suppressor Protein p53 - genetics; Vimentin - genetics; Vimentin - metabolism; United States > US; Renoprotection; Extracellular matrix; Inflammation; Cancer chemotherapy; Apoptosis; p53

Cisplatin is widely used for cancer chemotherapy, but nephrotoxicity is a major dose-limiting side effect. Our recent studies in vitro have shown that pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorated cisplatin nephrotoxicity and that the renoprotection with PACAP38 was mediated...